AstraZeneca and Absci Collaborate on Cancer Drug Development
AstraZeneca has entered into a partnership with AI biologics firm Absci to develop an antibody for cancer treatment. The collaboration aims to utilize generative artificial intelligence to design improved antibody therapeutics. The deal includes an upfront fee, research and development funding, milestone payments, and royalties on product sales. The specific type of cancer being targeted was not disclosed.